Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521

Watchlist Manager
Zhejiang Huahai Pharmaceutical Co Ltd Logo
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Watchlist
Price: 17.57 CNY 1.04% Market Closed
Market Cap: 25.5B CNY
Have any thoughts about
Zhejiang Huahai Pharmaceutical Co Ltd?
Write Note

Zhejiang Huahai Pharmaceutical Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Huahai Pharmaceutical Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Accounts Payable
ÂĄ1.1B
CAGR 3-Years
35%
CAGR 5-Years
24%
CAGR 10-Years
17%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accounts Payable
ÂĄ163.8m
CAGR 3-Years
10%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accounts Payable
ÂĄ470.9m
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
20%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accounts Payable
ÂĄ1.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
15%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accounts Payable
ÂĄ4.5B
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accounts Payable
ÂĄ307.9m
CAGR 3-Years
65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Huahai Pharmaceutical Co Ltd
Glance View

Market Cap
25.8B CNY
Industry
Pharmaceuticals

Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Taizhou, Zhejiang and currently employs 7,019 full-time employees. The company went IPO on 2003-03-04. The firm's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The firm also provides related technical support services. The firm distributes its products in domestic and overseas markets.

Intrinsic Value
25.58 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Zhejiang Huahai Pharmaceutical Co Ltd's Accounts Payable?
Accounts Payable
1.1B CNY

Based on the financial report for Jun 30, 2024, Zhejiang Huahai Pharmaceutical Co Ltd's Accounts Payable amounts to 1.1B CNY.

What is Zhejiang Huahai Pharmaceutical Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
17%

Over the last year, the Accounts Payable growth was 40%. The average annual Accounts Payable growth rates for Zhejiang Huahai Pharmaceutical Co Ltd have been 35% over the past three years , 24% over the past five years , and 17% over the past ten years .

Back to Top